glp-1 consumer behavior Is Rewriting the Food Retail Playbook Consumer Behavior Data for GLP-1

According to the EMAs findings, people who take Ozempic are two times more likely to experience a condition that causes sudden, potentially irreversible vision loss

Global cuisine also continues to gain, especially among younger shoppers

EMPA-KIDNEY (Empagliflozin in Patients with Chronic Kidney Disease) showed that in patients with chronic kidney disease, empagliflozin leads to a lower risk of progression of kidney disease [29]

The incidence of depression or self-harm was 8.2 vs 11.7 events/1,000 person-years in the DPP-4i-cohort and 18.2 vs 13.6 events/1,000 person-years in the GLP-1 RA cohort for incretin-based therapies vs sulfonylureas, respectively